Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
In this issue of Hepatology, Noureddin et al. describe an innovative application of an emerging magnetic resonance imaging (MRI)-based biomarker, proton density fat-fraction (PDFF), for quantification of hepatic steatosis in patients with nonalcoholic steatohepatitis (NASH).1 In this study, 50 patients with biopsy-proven NASH were enrolled in a randomized double-blinded placebo-controlled trial. Patients were randomized to receive placebo or colesevelam, an agent known to reduce elevated low-density lipoprotein (LDL) and to improve glycemic control in adults with type II diabetes. The authors performed cross-sectional comparisons of MRI-derived PDFF with MR spectroscopy (MRS)-derived PDFF and nontargeted liver biopsy, at baseline and after 24 weeks of treatment. This study demonstrated excellent agreement and correlation between MRI and MRS, and also demonstrated excellent correlation between both MRI and MRS with histology-derived steatosis grade. Perhaps most interesting, the authors determined that longitudinal changes in MRI-derived PDFF was more sensitive to detection of changes in liver fat than biopsy, with changes in liver fat paralleling changes in body weight and serum aminotransferases between baseline and week 24. These exciting results demonstrate the utility of quantitative MRI methods for treatment monitoring using a novel, noninvasive imaging-based biomarker of hepatic steatosis. Biopsy is and will remain the clinical gold standard for the diagnosis, grading, and staging of diffuse liver disease. However, emerging imaging-based biomarkers of diffuse liver disease, such as MRI-derived PDFF, will play an important complementary role in the management of patients with liver disease. Although cost and the invasive nature of biopsy are relative barriers, the most important limitation of biopsy is its known sampling variability.2 The high variability between repeated measurements limits the ability of biopsy to quantify longitudinal changes in features of diffuse liver disease during an intervention such as weight loss or drug therapy. Of course, biopsy plays a central diagnostic role given its ability to evaluate other features of diffuse liver disease such as inflammation, fibrosis, ballooning degeneration, etc. Biopsy can also characterize disease processes through the histological distribution of disease features at the level of the portal sinusoid. This characterization is beyond the capability of current radiological methods such as MRI. MRI is an established noninvasive method for performing a wide variety of diagnostic procedures including imaging of the abdomen, without the use of ionizing radiation. It is widely regarded as the best noninvasive method to assess focal liver lesions and, qualitatively, many features of diffuse liver disease, such as hepatic steatosis and iron overload, and, in the endstages, fibrosis. MRI works by magnetically polarizing the nuclear spin of protons in the body, which are in very high concentration in water and fat (∼55M). Radiofrequency (RF) energy (64 MHz at 1.5T, 128 MHz at 3T) is transmitted into the body, and the resulting signals emitted from these "excited" protons are subsequently received using receive coils placed on the body. Because of higher electronic shielding of the protons in triglycerides, the proton signal from triglycerides is ∼217 Hz slower than water (at 1.5T, 434 Hz at 3T). This "chemical shift" is exploited by "chemical shift encoded" MRI methods, such as that described by Noureddin et al. Using these methods, the relative concentration of signal from protons of water and fat can be determined. It is with great serendipity that only the abnormal accumulation of fat (triglycerides in vacuoles) is visible with MRI. Protons from cholesterol, sphingolipids, phospholipids, and other fat molecules that comprise cell membranes and organelles yield no visible MRI signal and can only be detected using solid-state nuclear magnetic resonance (NMR) methods. MRI is a rich modality whose signal depends on a large number of factors that can be exploited to generate a vast number of contrast mechanisms used for diagnosis. For example, MRI is sensitive to the presence of tissue water content, met-hemoglobin, oxygen concentration, the diffusion of water in tumors, tissue perfusion, blood flow in large vessels, melanin, fat, iron, and many other factors that make this modality such a versatile and powerful clinical tool. Unfortunately, this dependence of the MRI signal on so many factors has, paradoxically, limited the ability of MRI to quantify features of disease, because many of these factors alter the MRI signal in unanticipated ways. As a result of these confounding factors, conventional MRI methods attempting to quantify triglyceride concentration have lacked robustness to changes in acquisition parameters. Historically, this has led to poor reproducibility across institutions, MRI platforms, MRI manufacturers, and also field strength (1.5T and 3
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Noureddin, M., Lam, J., Peterson, M. R., Middleton, M., Hamilton, G., Le, T.-A., Bettencourt, R., Changchien, C., Brenner, D. A., Sirlin, C., et al. (2013) · Hepatology · doi:10.1002/hep.26455 · Cited by 550 · cited 3×
“T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accu-”
BackgroundMethod
Cited by
Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662
“In addition, MRI-PDFF allows for objective, quantitative fat fraction measurements throughout the various segments of the liver with minimal sampling variability (29).”
BackgroundHeritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study
Loomba, R., Schork, N., Chen, C.-H., Bettencourt, R., Bhatt, A., Ang, B., Nguyen, P., Hernandez, C., Richards, L., Salotti, J., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.011 · Cited by 389
Caussy, C., Alquiraish, M. H., Nguyen, P., Hernandez, C., Cepin, S., Fortney, L. E., Ajmera, V., Bettencourt, R., Collier, S., Hooker, J., et al. (2018) · Hepatology · doi:10.1002/hep.29639 · Cited by 375
Tang, A., Desai, A., Hamilton, G., Wolfson, T., Gamst, A., Lam, J., Clark, L., Hooker, J., Chavez, T., Ang, B. D., et al. (2015) · Radiology · doi:10.1148/radiol.14140754 · Cited by 356
Loomba, R., Sirlin, C. B., Ang, B., Bettencourt, R., Jain, R., Salotti, J., Soaft, L., Hooker, J., Kono, Y., Bhatt, A., et al. (2015) · Hepatology · doi:10.1002/hep.27647 · Cited by 344
Metadata
- Authors
- Reeder, S. B.
- Venue
- Hepatology
- Published
- 2013-10-11
- Volume
- 58
- Issue
- 6
- Pages
- 1877-1880
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2054143624
- Cited by
- 50
- References
- 1
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.